These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 25722448)

  • 1. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.
    Banerjee SR; Foss CA; Pullambhatla M; Wang Y; Srinivasan S; Hobbs RF; Baidoo KE; Brechbiel MW; Nimmagadda S; Mease RC; Sgouros G; Pomper MG
    J Nucl Med; 2015 Apr; 56(4):628-34. PubMed ID: 25722448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation and Pilot Clinical Study of Al
    Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
    J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using
    Yusufi N; Wurzer A; Herz M; D'Alessandria C; Feuerecker B; Weber W; Wester HJ; Nekolla S; Eiber M
    J Nucl Med; 2021 Aug; 62(8):1106-1111. PubMed ID: 33443072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and pre-clinical evaluation of a new class of high-affinity
    Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of
    Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
    Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.
    Zechmann CM; Afshar-Oromieh A; Armor T; Stubbs JB; Mier W; Hadaschik B; Joyal J; Kopka K; Debus J; Babich JW; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1280-92. PubMed ID: 24577951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single Chelator-Minibody Theranostic Agents for
    Ho KV; Tatum DS; Watkinson L; Carmack T; Jia F; Mascioni A; Maitz CA; Magda D; Anderson CJ
    J Nucl Med; 2024 Sep; 65(9):1435-1442. PubMed ID: 39142831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
    J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
    Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG
    Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing Treatment Efficacy of
    Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and preclinical evaluation of an Al
    Boschi S; Lee JT; Beykan S; Slavik R; Wei L; Spick C; Eberlein U; Buck AK; Lodi F; Cicoria G; Czernin J; Lassmann M; Fanti S; Herrmann K
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2122-2130. PubMed ID: 27329046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.
    Herrmann K; Bluemel C; Weineisen M; Schottelius M; Wester HJ; Czernin J; Eberlein U; Beykan S; Lapa C; Riedmiller H; Krebs M; Kropf S; Schirbel A; Buck AK; Lassmann M
    J Nucl Med; 2015 Jun; 56(6):855-61. PubMed ID: 25883128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of
    Banerjee SR; Kumar V; Lisok A; Plyku D; Nováková Z; Brummet M; Wharram B; Barinka C; Hobbs R; Pomper MG
    J Nucl Med; 2019 Mar; 60(3):400-406. PubMed ID: 30237212
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
    J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
    Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
    J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
    J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.